Drugs / RG1530
RG1530
also known as
R-1530
Small molecule targets AURKA, FGFR1, FGFR2, FLT3, PDGFRB, PLK4 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00493155 | Oct 2005 → Feb 2009 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG1530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00493155 ↗ |
| Known as | R-1530 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1980391 ↗ |
| Action | Inhibit | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL1980391 ↗5“Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL1980391 ↗ “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1980391 ↗ “Serine/threonine-protein kinase PLK4 inhibitor” CHEMBL1980391 ↗ “Fibroblast growth factor receptor 2 inhibitor” CHEMBL1980391 ↗ “Fibroblast growth factor receptor 1 inhibitor” CHEMBL1980391 ↗ |
| Modality | Small molecule | — CHEMBL1980391 ↗ |
| Route | Oral | “Administered po at escalating doses (10 cohorts)” NCT00493155 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL1980391 ↗ |
| Target | FGFR1 | “Fibroblast growth factor receptor 1 inhibitor” CHEMBL1980391 ↗ |
| Target | FGFR2 | “Fibroblast growth factor receptor 2 inhibitor” CHEMBL1980391 ↗ |
| Target | FLT3 | “Tyrosine-protein kinase receptor FLT3 inhibitor” CHEMBL1980391 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL1980391 ↗ |
| Target | PLK4 | “Serine/threonine-protein kinase PLK4 inhibitor” CHEMBL1980391 ↗ |